Literature DB >> 2591563

Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys.

J P Wolf1, J G Hsiu, T L Anderson, A Ulmann, E E Baulieu, G D Hodgen.   

Abstract

The noncompetitive antiestrogenic effects of RU 486 were examined using estradiol (E2)-treated ovariectomized monkeys given RU 486, progesterone (P), or both. The E2-induced luteinizing-hormone (LH) surge of control animals was abrogated by P and/or RU 486. Secretory transformation by P was inhibited by RU 486 coadministration. RU 486 alone (1 mg/kg) induced endometrial secretory transformation, but higher doses (5 mg/kg) inhibited proliferation and secretory activity. Thus in the presence of P, RU 486 is antagonistic but, in absence of P, exhibits endometrial progestational effects at low doses and an antiproliferative (antiestrogenic) effect at higher doses. These data encourage continued evaluation of RU 486 as a potential contraceptive agent acting at the pituitary and/or endometrial level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591563     DOI: 10.1016/s0015-0282(16)53174-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  In vivo antiestrogenic activity of mifepristone in the rat.

Authors:  J Nedvídková; V Schreiber; L Stárka
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

2.  Mifepristone-exposured human endometrial endothelial cells in vitro.

Authors:  Malin Helmestam; Karin Elvine Lindgren; Anneli Stavreus-Evers; Matts Olovsson
Journal:  Reprod Sci       Date:  2013-07-24       Impact factor: 3.060

3.  Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques.

Authors:  Robert M Brenner; Ov D Slayden; Anita Nath; Y Y Tsong; Regine Sitruk-Ware
Journal:  Contraception       Date:  2009-12-16       Impact factor: 3.375

Review 4.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

5.  Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone.

Authors:  Christopher R McCartney; Susan K Blank; John C Marshall
Journal:  Endocrine       Date:  2009-07-16       Impact factor: 3.633

Review 6.  A benefit-risk assessment of medical treatment for uterine leiomyomas.

Authors:  Vincenzo De Leo; Giuseppe Morgante; Antonio La Marca; Maria Concetta Musacchio; Massimo Sorace; Chiara Cavicchioli; Felice Petraglia
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Predisposing factors for fibroids and outcome of laparoscopic myomectomy in infertility.

Authors:  Prakash Trivedi; Mohini Abreo
Journal:  J Gynecol Endosc Surg       Date:  2009-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.